Patents by Inventor Mikhail Kolonin

Mikhail Kolonin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220235357
    Abstract: The present subject matter relates to the use of one or more inhibitors to treat a disease, e.g., cancer, in a subject. The presently disclosed subject matter provides for compositions and methods for treating a subject using a cancer transition inhibitor, an inhibitor that reduces the expression level of a marker of the transition of adipose-derived stromal cells (ASCs) to COL11A1-expressing cancer-associated fibroblasts (CAFs).
    Type: Application
    Filed: December 28, 2021
    Publication date: July 28, 2022
    Applicants: The Trustees of Columbia University in the City of New York, The University of Texas Health Science Center at Houston
    Inventors: Dimitris Anastassiou, Lingyi Cai, Kaiyi Zhu, Mikhail Kolonin
  • Publication number: 20130071326
    Abstract: The present invention provides modified stem cells that comprise a delivery system that comprises at least one microparticle or nanoparticle, wherein the at least one microparticle or nanoparticle comprises an active agent. The present invention also provides delivery methods that comprise the administration of the modified stem cells to a subject. Additional aspects of the present invention pertain to methods of making said modified stem cells.
    Type: Application
    Filed: March 17, 2011
    Publication date: March 21, 2013
    Applicant: Board of Regents of the University of Texas System
    Inventors: Jonathan O. Martinez, Ennio Tasciotti, Mikhail Kolonin, Mauro Ferrari
  • Publication number: 20120270808
    Abstract: Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct tissues or organs. Typically, the methods of the invention provide for peptide selection in a Minimal number of subjects and still provides a selectively binding peptide. In certain aspects, methods of identifying peptides that bind to multiple selected tissues or organs of an organism may comprise the steps of administering a phage display library to a first subject; obtaining a sample of two or more selected tissues; obtaining phage displaying peptides that bind to the samples from the first subject; enriching for peptides by administering phage isolated from the samples of the first subject to a second subject; obtaining a sample of two or more selected tissues from the second subject; and identifying the peptides displayed.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 25, 2012
    Inventors: Mikhail Kolonin, Wadih Arap, Renata Pasqualini
  • Publication number: 20100298233
    Abstract: Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population.
    Type: Application
    Filed: June 29, 2010
    Publication date: November 25, 2010
    Inventors: Renata Pasqualini, Wadih Arap, Mikhail Kolonin
  • Patent number: 7781565
    Abstract: Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: August 24, 2010
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Renata Pasqualini, Wadih Arap, Mikhail Kolonin
  • Publication number: 20090221505
    Abstract: Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct tissues or organs. Typically, the methods of the invention provide for peptide selection in a Minimal number of subjects and still provides a selectively binding peptide. In certain aspects, methods of identifying peptides that bind to multiple selected tissues or organs of an organism may comprise the steps of administering a phage display library to a first subject; obtaining a sample of two or more selected tissues; obtaining phage displaying peptides that bind to the samples from the first subject; enriching for peptides by administering phage isolated from the samples of the first subject to a second subject; obtaining a sample of two or more selected tissues from the second subject; and identifying the peptides displayed.
    Type: Application
    Filed: November 16, 2005
    Publication date: September 3, 2009
    Inventors: Mikhail Kolonin, Wadih Arap, Renata Pasqualini
  • Publication number: 20080003200
    Abstract: The compositions and methods include targeting peptides selective for tissue selective binding, particularly prostate and/or bone cancer, or adipose tissue. The methods may comprise targeting peptides that bind, for example, cell surface GRP78, IL-11R? in blood vessels of bone, or prohibitin of adipose vascular tissue. These peptides may be used to induce targeted apoptosis in the presence or absence of at least one pro-apoptotic peptide. Antibodies against such targeting peptides, the targeting peptides, or their mimeotopes may be used for detection, diagnosis and/or staging of a condition, such as prostate cancer or metastatic prostate cancer.
    Type: Application
    Filed: August 7, 2007
    Publication date: January 3, 2008
    Inventors: Wadih Arap, Mikhail Kolonin, Renata Pasqualini, Amado Zurita
  • Publication number: 20070248952
    Abstract: Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population.
    Type: Application
    Filed: March 9, 2007
    Publication date: October 25, 2007
    Inventors: Renata Pasqualini, Wadih Arap, Mikhail Kolonin
  • Publication number: 20060239968
    Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11R? and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and/or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.
    Type: Application
    Filed: October 30, 2002
    Publication date: October 26, 2006
    Inventors: Wadih Arap, Mikhail Kolonin, Paul Mintz, Renata Pasqualini, Amado Zurita
  • Publication number: 20060094672
    Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 OR SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.
    Type: Application
    Filed: August 30, 2002
    Publication date: May 4, 2006
    Inventors: Renata Pasqualini, Wadih Arap, Mikhail Kolonin
  • Publication number: 20050191294
    Abstract: The compositions and methods include targeting peptides selective for tissue selective binding, particularly prostate and/or bone cancer, or adipose tissue. The methods may comprise targeting peptides that bind, for example, cell surface GRP78, IL-11R? in blood vessels of bone, or prohibitin of adipose vascular tissue. These peptides may be used to induce targeted apoptosis in the presence or absence of at least one pro-apoptotic peptide. Antibodies against such targeting peptides, the targeting peptides, or their mimeotopes may be used for detection, diagnosis and/or staging of a condition, such as prostate cancer or metastatic prostate cancer.
    Type: Application
    Filed: December 30, 2004
    Publication date: September 1, 2005
    Inventors: Wadih Arap, Mikhail Kolonin, Renata Pasqualini, Amado Zurita